As We See It by ProQuest


The incoming FDA commissioner faces something akin to the theme of the old Mission Impossible television series as the agency admits to yet another management gaffe in its bizarre "disinvitation," at Eli Lilly's request, of a dissident voice on an advisory committee days before it was to vote on the company's new drug, prasugrel. Absent that voice, belonging to Sanjay Kaul, a Cedars-Sinai Heart Institute cardiologist, the panel voted 9-0 in favor of prasugrel's approval.

More Info
To top